tiprankstipranks
Advertisement
Advertisement

AVBP Stock Latest News

ArriVent Biopharma announces FDA clearance of ARR-002 NDA
The FlyArriVent Biopharma announces FDA clearance of ARR-002 NDA
1d ago
AVBP
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
11d ago
AVBP
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
PremiumThe Fly
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
15d ago
AVBP
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
PremiumThe Fly
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
2M ago
AVBP
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
PremiumCompany Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
2M ago
8K
AVBP
ArriVent Biopharma assumed with a Buy at BTIG
PremiumThe FlyArriVent Biopharma assumed with a Buy at BTIG
2M ago
AVBP
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
Premium
Ratings
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
2M ago
AVBP
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
Premium
The Fly
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
2M ago
AVBP
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
PremiumThe Fly
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
2M ago
AVBP
ArriVent Biopharma price target raised to $33 from $31 at Citi
PremiumThe Fly
ArriVent Biopharma price target raised to $33 from $31 at Citi
2M ago
AVBP
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
PremiumThe Fly
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
3M ago
ET
ABR
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
PremiumRatings
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
4M ago
AVBP
ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
PremiumRatingsArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
4M ago
AVBP
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
5M ago
AVBP
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study
Premium
The Fly
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study
5M ago
AVBP
3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
5M ago
AMZN
APGE
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential
PremiumThe Fly
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential
5M ago
AVBP
ArriVent Biopharma initiated with a Buy at BTIG
PremiumThe Fly
ArriVent Biopharma initiated with a Buy at BTIG
5M ago
AVBP
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment
PremiumRatings
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment
5M ago
AVBP
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results
PremiumRatingsBuy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results
5M ago
AVBP
ArriVent Biopharma initiated with a Buy at Truist
Premium
The Fly
ArriVent Biopharma initiated with a Buy at Truist
5M ago
AVBP
ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target
Premium
Ratings
ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target
6M ago
AVBP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >